SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-019467
Filing Date
2021-08-12
Accepted
2021-08-12 14:15:36
Documents
49
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1177590
2 ex31-1.htm EX-31.1 11171
3 ex31-2.htm EX-31.2 11069
4 ex32.htm EX-32 4869
  Complete submission text file 0001493152-21-019467.txt   3887906

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20210630.xsd EX-101.SCH 27263
6 XBRL CALCULATION FILE pvct-20210630_cal.xml EX-101.CAL 42265
7 XBRL DEFINITION FILE pvct-20210630_def.xml EX-101.DEF 131807
8 XBRL LABEL FILE pvct-20210630_lab.xml EX-101.LAB 231182
9 XBRL PRESENTATION FILE pvct-20210630_pre.xml EX-101.PRE 188706
10 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 450606
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 211166954
SIC: 2834 Pharmaceutical Preparations